4 results match your criteria: "and Howard University College of Medicine[Affiliation]"
Clin Exp Rheumatol
February 2024
Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore; and Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objectives: To assess nailfold video capillaroscopic (NVC) abnormalities and their association with clinical features, myositis-specific autoantibodies (MSA), and myositis-associated antibodies (MAA) in a large multi-ethnic cohort of patients with idiopathic inflammatory myopathies (IIM).
Methods: We recruited 155 IIM patients from three centres in Mexico, Spain, and the USA. We evaluated the clinical and laboratory features of the patients and performed semiquantitative and quantitative analyses of the NVC.
ACR Open Rheumatol
April 2023
Washington DC Veterans Affairs Medical Center, Georgetown University, and Howard University College of Medicine, Washington, DC.
Objective: Our objective was to evaluate the factors associated with regional variation of rheumatoid arthritis (RA) disease burden in the US.
Methods: In a retrospective cohort analysis of Rheumatology Informatics System for Effectiveness (RISE) registry data, seropositivity, RA disease activity (Clinical Disease Activity Index [CDAI], Routine Assessment of Patient Index Data-version 3 [RAPID3]), socioeconomic status (SES), geographic region, health insurance type, and comorbidity burden were recorded. An Area Deprivation Index score of more than 80 defined low SES.
Br J Dermatol
December 2021
Ramón y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain.
Background: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for treatment.
Objectives: To enable data to be collected worldwide on FFA using common criteria and assessment methods.